AbbVie Stock Climbs 26% on Skyrizi and Rinvoq Growth

AbbVie (ABBV) shares have climbed 26% this year alongside a 0.14% session move, propelled by strong financial performance across its core pharmaceutical portfolio. Traders are tracking the company's medium-term outlook as key growth pillars drive sales.

### Session Tape - ABBV: +0.14% session move

## Catalyst Analysis: Growth Pillars and Financial Performance The pharmaceutical giant is benefiting from strong momentum across its primary growth drivers, Skyrizi and Rinvoq, which are firing on all cylinders. In the first half of the year, medicine sales generated almost $10 billion, marking a 27% increase year-over-year. Additionally, AbbVie features a gross margin of 71.42% and offers a forward dividend yield of 2.5%, outpacing the S&P 500's average of 1.1%. Management is also addressing long-term positioning, focusing on succession plans and new pipeline drugs as the decade progresses.

## Technical Analysis & Key Risk Watch

Key levels for $NVDA+WL (educational): R2 $219.86 · R1 $218.47 · last $217.09 · S1 $217.00 · S2 $216.40.

Trading volume stands at 6.2 million against an average volume of 4.8 million. The equity trades within a day's range of $278.01 to $285.76, with a 52-week range spanning from $190.75 to $291.40 and an implied market capitalization of approximately $503.28 billion. Market participants are monitoring volume persistence above the 4.8 million average baseline to gauge institutional accumulation.

### Money Play As AbbVie advances its pipeline and maintains a 2.5% forward yield, market participants monitor valuation stability near recent range highs.